SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(Amendment No. 5)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
THERAVANCE BIOPHARMA, INC.
(Name of Subject Company (Issuer) and Filing Person (as Offeror))
ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE
(Title of Class of Securities)
G8807B106
(CUSIP Number of Class of Securities)
Brett Grimaud
General Counsel
c/o Theravance Biopharma US, Inc.
901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000
(Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons)
with copies to:
Jeffrey R. Vetter
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
550 Allerton St.
Redwood City, California 94063
(650) 321-2400
¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
¨ third-party tender offer subject to Rule 14d-1.
x issuer tender offer subject to Rule 13e-4.
¨ going-private transaction subject to Rule 13e-3.
¨ amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results of the tender offer: x
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
¨ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
¨ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
INTRODUCTORY STATEMENT
This Amendment No. 5 (the “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any subsequent amendments and supplements thereto, the “Schedule TO”) filed by Theravance Biopharma, Inc., a Cayman Islands exempted company (the “Company”), with the Securities and Exchange Commission on September 28, 2022. The Schedule TO relates to the offer by the Company to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the “Shares”) for cash at a purchase price not greater than $10.50 nor less than $9.75 per Share, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated September 28, 2022 (the “Offer to Purchase”) and the related Letter of Transmittal (the “Letter of Transmittal”). Copies of the Offer to Purchase and the Letter of Transmittal were previously filed as Exhibits (a)(1)(i) and (a)(1)(ii) to the Schedule TO, respectively.
The Amendment is filed in satisfaction of the reporting requirements of Rule 13e-4(c)(4) promulgated under the Securities Exchange Act of 1934, as amended. Only those items amended or supplemented are reported in this Amendment. Except as specifically provided herein, the information contained in the Schedule TO remains unchanged, and this Amendment does not modify any of the information previously reported on the Schedule TO.
Item 8. Interest of Securities of the Subject Company.
Item 8(b) of the Schedule TO is hereby amended and supplemented by adding the following text:
On November 15, 2022, Rick Winningham acquired 817 Shares under the Company’s 2013 Employee Share Purchase Plan at $6.7915 per Share;
On November 15, 2022, Andrew Hindman acquired 1,264 Shares acquired under the Company’s 2013 Employee Share Purchase Plan at $6.7915 per Share;
On November 18, 2022, Mr. Hindman sold 65,000 Shares in open market transactions at a weighted average sale price of $11.0191;
On November 20, 2022, Mr. Winningham had 15,804 Shares withheld at a price per share of $10.85 to satisfy tax withholding obligations on vesting of previously granted restricted stock units;
On November 20, 2022, Mr. Hindman had 25,057 Shares withheld at a price per share of $10.85 to satisfy tax withholding obligations on vesting of previously granted restricted stock units;
On November 20, 2022, Rick Graham had 27,350 Shares withheld at a price per share of $10.85 to satisfy tax withholding obligations on vesting of previously granted restricted stock units; and
On November 20, 2022, Rhonda Farnum had 23,268 Shares withheld at a price per share of $10.85 to satisfy tax withholding obligations on vesting of previously granted restricted stock units.
Item 11. Additional Information.
Item 11 is hereby amended and supplemented as follows:
On November 22, 2022, the Company issued a press release announcing the final results of the Offer, which expired at midnight, New York City time, at the end of the day on November 17, 2022. A copy of such press release is filed as Exhibit (a)(5)(v) to this Schedule TO and is incorporated herein by reference.
Item 12. Exhibit Index.
(a)(5)(ii)* | | Press Release dated September 28, 2022. |
(a)(5)(iii)* | Press Release dated November 7, 2022. | |
(a)(5)(iv)* | Press Release dated November 18, 2022. | |
(a)(5)(v)+ | Press Release dated November 22, 2022. |
* Filed Previously
+ Filed Herewith
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: November 22, 2022
THERAVANCE BIOPHARMA, INC. | ||
By: | /s/ Andrew ASA Hindman | |
Andrew ASA Hindman | ||
CFO |